| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23028 |
| Drug | Mavacamten |
| Brand | Camzyos® |
| Indication | Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 19/05/2023 |
| Rapid review completed | 27/06/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mavacamten compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 26/07/2023 |
| Pre-submission consultation with Applicant | 12/09/2023 |
| Full submission received from Applicant | 20/12/2023 |
| Preliminary review sent to Applicant | 16/07/2024 |
| NCPE assessment re-commenced | 14/08/2024 |
| Factual accuracy sent to Applicant | 12/12/2024 |
| NCPE assessment re-commenced | 19/12/2024 |
| NCPE assessment completed | 20/01/2025 |
| NCPE assessment outcome | The NCPE recommends that mavacamten not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.